Evidence map›Paper›PMID 39482500›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Synthesis, preclinical assessment, and first-in-human study of [

Lu Hou, Zhiyong Chen, Fanfan Chen, Lianghe Sheng, Weijian Ye, Yingchu Dai, Xiaoyu Guo, Chenchen Dong, Guocong Li, Kai Liao and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Development and evaluation of a novel deuterated fluorine-18 PET tracer for MAO-B imaging.American journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Lu HouCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine, & Key Laboratory of Basic and Translational Research On Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Zhiyong ChenDepartment of Neurosurgery, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Fanfan ChenDepartment of Neurosurgery, Shenzhen Key Laboratory of Neurosurgery, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518025, China.
Lianghe ShengDepartment of Oncology, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Weijian YeCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine, & Key Laboratory of Basic and Translational Research On Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Yingchu DaiDepartment of Radiotherapy and Oncology, The Affiliated Hospital of Jiangnan University, Wuxi, 214122, China.
Xiaoyu GuoDepartment of Neurosurgery, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Chenchen DongCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine, & Key Laboratory of Basic and Translational Research On Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Guocong LiCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine, & Key Laboratory of Basic and Translational Research On Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Kai LiaoCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine, & Key Laboratory of Basic and Translational Research On Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Yinlong LiDepartment of Radiology and Imaging Sciences, Emory University, 1364 Clifton Rd, Atlanta, GA, 30322, USA.
Jie MaCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine, & Key Laboratory of Basic and Translational Research On Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Huiyi WeiCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine, & Key Laboratory of Basic and Translational Research On Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Wenqing RanCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine, & Key Laboratory of Basic and Translational Research On Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Jingjie ShangCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine, & Key Laboratory of Basic and Translational Research On Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Xueying LingCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine, & Key Laboratory of Basic and Translational Research On Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Jimmy S PatelDepartment of Radiology and Imaging Sciences, Emory University, 1364 Clifton Rd, Atlanta, GA, 30322, USA.
Steven H LiangDepartment of Radiology and Imaging Sciences, Emory University, 1364 Clifton Rd, Atlanta, GA, 30322, USA. steven.liang@emory.edu.
Hao XuCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine, & Key Laboratory of Basic and Translational Research On Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China. txh@jnu.edu.cn.
Lu WangCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine, & Key Laboratory of Basic and Translational Research On Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China. l_wang1009@foxmail.com.ORCID 0000-0002-8049-1991

Funding

Guangzhou Science and Technology Program 202206010106Guangzhou Science and Technology Program 2023A03J0610Guangzhou Science and Technology Program 2023A04J1921National Natural Science Foundation of China 82071974National Natural Science Foundation of China 82202225National Natural Science Foundation of China 82371998the Clinical Frontier Technology Program of the First Affiliated Hospital of Jinan University JNU1AF-CFTP-2022-a01214the Guangdong Science and Technology Planning Project, China 2022A0505050042
6 · The paper itself

Abstract

purposeTumor-to-background ratio (TBR) is a critical metric in oncologic PET imaging. This study aims to enhance the TBR of [

methods[

results[

conclusionWe successfully synthesized the novel PET radiotracer [

trial registrationChiCTR2400081576, registration date: 2024-03-05, https://www.chictr.org.cn/bin/project/edit?pid=206162.

Indexed as

Brain NeoplasmsDideoxynucleosidesPositron-Emission TomographyRadiopharmaceuticalsAnimalsChemistry Techniques, SyntheticFemaleGliomaHumansMacaca fascicularisMaleMiceMiddle AgedRatsTissue DistributionalovudineDideoxynucleosidesRadiopharmaceuticals[18F]d 4-FETBrain tumour imagingGliomaPET-MRITBR

Identifiers

PMID39482500

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.